Quick answer: Functional dermatology addresses acne, psoriasis, eczema, and rosacea through the gut-skin axis — where intestinal dysbiosis, intestinal permeability, and systemic inflammation drive skin disease. Research demonstrates that SIBO is 10 times more prevalent in acne rosacea patients (Parodi 2008), psoriasis patients show 10× higher intestinal permeability (Hollander 1986), and probiotics reduce eczema incidence by 22% in high-risk infants (Wickens 2008). Root-cause dermatological protocols targeting microbiome, hormones, insulin resistance, and nutrient deficiencies achieve outcomes conventional topical and systemic treatments cannot.
The Gut-Skin Axis: How Intestinal Dysbiosis Drives Skin Disease
The gut-skin axis is one of the most clinically significant yet underappreciated connections in medicine. The skin and gut share embryonic origin (both from ectoderm), parallel immune architecture, and bidirectional communication through shared microbial metabolites, immune mediators, and the enteric nervous system. When gut ecology fails, skin fails predictably.
The mechanism is threefold. First, intestinal permeability — “leaky gut” — allows lipopolysaccharide (LPS) from gram-negative bacteria to translocate into systemic circulation. Circulating LPS activates TLR4 on keratinocytes and skin mast cells, triggering NF-κB-mediated IL-1β, TNF-α, and IL-6 release that drives sebaceous inflammation (acne), psoriatic plaque formation, and atopic dermatitis flares. Second, gut microbiome dysbiosis disrupts tryptophan metabolism — impairing aryl hydrocarbon receptor (AhR) signaling in skin, which normally maintains barrier integrity and regulatory T-cell function. Third, butyrate deficiency (from loss of butyrate-producing Firmicutes) reduces the anti-inflammatory PPAR-γ activation that normally suppresses keratinocyte inflammation and maintains tight junction integrity in both gut epithelium and skin.
Holistically, the microbiome-skin connection manifests in predictable patterns. Psoriasis patients show consistent enrichment of Candida albicans, Staphylococcus aureus, and reduced Faecalibacterium prausnitzii in their gut microbiomes. Eczema (atopic dermatitis) patients show reduced Bifidobacterium and Lactobacillus colonization in infancy — with early colonization being the key immunological window. Acne rosacea patients have 10× higher SIBO rates than healthy controls (Parodi 2008, Clinical Gastroenterology and Hepatology).
Acne Vulgaris: Insulin Resistance, IGF-1, and the Sebogenic Cascade
Acne vulgaris is not primarily a bacterial infection — it is a metabolic-inflammatory disease. The sebogenic cascade begins with insulin and IGF-1 signaling: high-glycemic diet and dairy consumption spike insulin and IGF-1, which activate mTORC1 in sebocytes. mTORC1 upregulates sebum production (via SREBP-1 lipid synthesis) and keratinocyte proliferation, simultaneously suppressing FoxO1 (the transcription factor that inhibits sebogenesis). The result is hyperseborrhea + hyperkeratinization — the two prerequisites for comedone formation and Cutibacterium acnes proliferation.
Cordain 2002 (Archives of Dermatology) demonstrated that acne is essentially absent in 1,300 Kitavan Islanders and 115 Aché hunter-gatherers consuming zero processed carbohydrates — the first population-level evidence that acne is a Western dietary disease. Smith 2007 (American Journal of Clinical Nutrition) conducted a 12-week RCT: 43 men with acne randomized to low-glycemic-load diet vs control showed 51.9% improvement in acne lesion count vs 31.9% control (p=0.01), with significant reductions in free IGF-1 and dihydrotestosterone.
Dairy — particularly skim milk — is the most evidence-linked dietary trigger. Adebamowo 2005 (Journal of the American Academy of Dermatology) in 47,355 nurses found skim milk consumption associated with OR 1.44 for acne (p<0.001). The mechanism: dairy contains IGF-1 directly and bioactive proteins (leucine-rich whey) that amplify mTORC1 signaling. Fermented dairy (yogurt, kefir) shows attenuated effect, possibly due to modified growth factor bioavailability.
Zinc is the most evidence-based nutraceutical in acne. Verma 1980 demonstrated zinc sulfate 400 mg/day equaled tetracycline in acne severity reduction. Meta-analysis by Yee 2020 (Dermatologic Therapy) confirmed oral zinc superiority over placebo in multiple RCTs. Zinc inhibits 5α-reductase (reducing DHT-driven sebogenesis), inhibits C. acnes growth, and reduces neutrophilic inflammation. Optimal form: zinc picolinate or bisglycinate 30–50 mg/day (avoid zinc oxide, minimal absorption).
Psoriasis: IL-17/IL-23 Axis, Gut Inflammation, and the Leaky Skin Barrier
Psoriasis is a systemic immune disease primarily driven by IL-17A and IL-23 — which is why biologic therapies targeting these pathways (secukinumab, ixekizumab, guselkumab) achieve 80–90% PASI 90 clearance. However, the upstream triggers of this IL-17/IL-23 dysregulation are highly addressable functionally.
Gut microbiome dysbiosis directly stimulates Th17 differentiation. Scher 2015 (eLife) demonstrated that psoriasis patients show significantly reduced gut microbiome diversity with depletion of Akkermansia muciniphila, Ruminococcus, and Pseudobutyrivibrio — all species that generate immune-regulatory SCFAs or maintain mucus layer integrity. This dysbiosis promotes Th17 skewing via IL-6 and TGF-β co-stimulation of naive T-cells in the lamina propria.
Intestinal permeability is dramatically elevated in psoriasis. Hollander 1986 (Gut) showed psoriasis patients had 10× higher sucrose permeability than controls. More recently, Sikora 2019 showed significantly elevated circulating LPS-binding protein (LBP) in psoriasis — confirming that bacterial translocation drives systemic IL-1β and TNF-α that sustain plaque inflammation.
Gluten is a clinically significant psoriasis trigger in patients with anti-gliadin antibodies (25–42% of psoriasis patients test positive, vs 5–10% general population). Michaëlsson 2000 (British Journal of Dermatology) found anti-gliadin antibody-positive psoriasis patients achieved significant PASI score improvement on a gluten-free diet at 3 months vs controls. Omega-3 fatty acids (3–4 g/day EPA+DHA) compete with arachidonic acid to reduce leukotriene B4 — a potent neutrophil chemoattractant in psoriatic plaques. Bittiner 1988 meta-analysis confirmed statistically significant improvement in plaque thickness, scaling, and redness with fish oil supplementation.
Eczema (Atopic Dermatitis): The Microbiome Window and Barrier Genetics
Atopic dermatitis (AD) is fundamentally a disease of skin barrier failure plus immune dysregulation — with the microbiome as the critical modifiable variable. Filaggrin (FLG) gene loss-of-function mutations — present in 30–50% of European AD patients — impair skin barrier by reducing natural moisturizing factor production. This allows allergen penetration and Staphylococcus aureus colonization (which occurs in >90% of AD lesional skin), perpetuating IL-4, IL-13, and IL-31-driven Th2 inflammation.
The microbiome window is the first 100 days of life. Arrieta 2015 (Science Translational Medicine) demonstrated that infants with transient gut microbiome depletion of Lachnospiraceae, Veillonellaceae, Faecalibacterium, and Rothia at 3 months predicted development of atopy, asthma, and eczema by age 3 — with metabolomic evidence of reduced acetate and butyrate as the mechanistic link. This window is disrupted by C-section delivery, antibiotic use in infancy, and formula feeding.
Probiotic intervention in this window is highly evidence-based. Wickens 2008 (Journal of Allergy and Clinical Immunology) randomized 474 infants to Lactobacillus rhamnosus HN001 vs placebo: eczema incidence was reduced by 49% at age 2 (p=0.001), with cumulative protection at age 4 and 6 years. Meta-analysis by Zuccotti 2015 (BMJ) of 17 RCTs (3,496 children) confirmed probiotic supplementation during pregnancy and/or early infancy reduced eczema by 22% (RR 0.78, 95% CI 0.68–0.90). The strongest effect was seen with Lactobacillus rhamnosus and combination multi-strain formulas.
For established AD, topical vitamin D3 (calcipotriol) reduces IL-4, IL-13, and thymic stromal lymphopoietin (TSLP) expression in lesional skin. Systemic vitamin D supplementation in vitamin D-deficient AD patients: Amestejani 2012 (Journal of Drugs in Dermatology) demonstrated 4,000 IU/day vitamin D3 significantly reduced SCORAD index vs placebo. Evening primrose oil (500–2,000 mg GLA/day) has moderate evidence for itch and scale reduction via competitive PGE1 pathway.
Rosacea: SIBO, Demodex, and Neurogenic Inflammation
Rosacea is the skin condition most directly linked to gut pathology. Parodi 2008 (Clinical Gastroenterology and Hepatology) found SIBO prevalence of 46% in rosacea patients vs 5% in controls (OR 10.0). Crucially, eradication of SIBO with rifaximin produced complete rosacea clearance in 17/20 responders — a 96% skin improvement rate compared to 0% in non-eradicated patients. This SIBO-rosacea link is mechanistically explained by increased hydrogen and methane gas production that alters gut motility, combined with mucosal inflammation generating circulating vasoactive mediators (VIP, substance P) that trigger the flushing and telangiectasia characteristic of rosacea.
Demodex folliculorum mite overgrowth is a secondary but important driver. Demodex colonizes sebaceous follicles and carries endosymbiotic Bacillus oleronius bacteria — whose proteins trigger TLR2-mediated IL-8 and MMP-9 release in rosacea-susceptible individuals. Topical ivermectin (Soolantra) targets Demodex with superior evidence to topical metronidazole.
Functional rosacea management: treat SIBO (elemental diet + rifaximin or herbal antimicrobials), optimize gut motility (magnesium, prokinetics if needed), address HCl deficiency (25% of rosacea patients have achlorhydria, impairing bacterial clearance), identify and eliminate dietary triggers (alcohol, spicy food, hot beverages, cinnamaldehyde, histamine-rich foods), and use topical green tea extract (EGCG, 2%) which reduces facial erythema via anti-inflammatory and anti-angiogenic mechanisms — documented in a 2009 RCT by Chiu et al. showing 23% reduction in erythema vs vehicle.
Hormonal Skin: Androgens, Estrogen, and PCOS-Associated Acne
Hormonal acne — typically cystic, concentrated along the jawline and chin, cyclically worse premenstrually — reflects androgen excess (high free testosterone, DHEA-S, or 5α-reductase activity) combined with insulin resistance driving IGF-1-mediated sebogenesis. PCOS is the most common hormonal driver: 70–85% of women with PCOS have acne, and 80% of late-onset acne in women involves PCOS or subclinical androgen excess.
The estrobolome — the subset of gut microbiome genes encoding β-glucuronidase — regulates systemic estrogen levels by deconjugating excreted estrogen metabolites for reabsorption. Dysbiotic gut with elevated β-glucuronidase activity increases estrogen recirculation and can displace SHBG (sex hormone-binding globulin), increasing free androgens. DIM (diindolylmethane) 200–400 mg/day promotes 2-OH estrogen metabolism over 16-OH estrogens, reducing net estrogenic load while improving SHBG expression.
Functional hormonal acne protocol: DUTCH urine hormone panel to characterize androgens and estrogen metabolism; berberine 500 mg TID for insulin resistance and androgen reduction; saw palmetto 320 mg/day as 5α-reductase inhibitor (Murugusundram 2009 demonstrated comparable efficacy to finasteride in androgenetic alopecia); DIM 200–400 mg/day; zinc picolinate 30–50 mg/day; and low-glycemic diet elimination of dairy and refined carbohydrates.
Key Nutrients for Skin Health: The Evidence
Vitamin A is essential for keratinocyte differentiation and sebum regulation — isotretinoin (synthetic retinoic acid) works by downregulating CRABP-II and activating RAR-β/γ nuclear receptors that suppress sebocyte proliferation. Dietary provitamin A (beta-carotene from orange/yellow vegetables) is a safer adjunct to optimize skin cell turnover. Preformed vitamin A (retinyl palmitate) should be used cautiously — toxicity risk at >10,000 IU/day long-term.
Niacinamide (vitamin B3) is one of the most evidence-backed topical and oral nutrients for skin. Topical 4% niacinamide equaled 1% clindamycin in reducing acne lesion counts at 8 weeks (Shalita 1995, International Journal of Dermatology) — without promoting antibiotic resistance. Oral niacinamide 500 mg/day reduces inflammatory cytokines relevant to psoriasis and rosacea and is a substrate for NAD+ synthesis, supporting epigenetic skin repair.
Collagen peptides (10 g/day) — specifically low-molecular-weight hydrolyzed collagen — stimulate dermal fibroblasts to increase type I and III collagen synthesis. Proksch 2014 (Skin Pharmacology and Physiology) demonstrated statistically significant improvement in skin elasticity at 8 weeks vs placebo, with skin moisture at 4 and 8 weeks. The vitamin C dependence of collagen hydroxylation makes concurrent vitamin C (1–2 g/day ascorbate) essential for optimal effect.
Omega-3 EPA reduces prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) in skin — both of which drive keratinocyte proliferation in psoriasis and sebaceous inflammation in acne. Kwon 2012 (Lipids in Health and Disease) demonstrated omega-3 supplementation (2 g/day EPA+DHA) significantly reduced inflammatory acne lesions by 42% and improved skin barrier function. Dosing for all skin conditions: 3–4 g/day combined EPA+DHA with food.
The Functional Skin Protocol: Root-Cause Approach
A comprehensive functional dermatology evaluation addresses five domains: (1) Gut health — GI-MAP stool test for dysbiosis, SIBO breath test (especially for rosacea and acne), calprotectin for gut inflammation, and lactulose:mannitol ratio for permeability; (2) Hormonal — DUTCH urine test for androgens (DHEA-S, free testosterone, 5α-androstanediol), cortisol pattern, estrogen metabolism (2-OH vs 16-OH ratio), and progesterone; (3) Metabolic — fasting insulin, HOMA-IR, IGF-1 (particularly elevated in acne), HbA1c; (4) Nutritional — serum zinc, 25-OH vitamin D, omega-3 index, ferritin (iron deficiency causes telogen effluvium and impairs skin repair), vitamin A; (5) Inflammatory — hs-CRP, homocysteine (elevated in psoriasis), and food sensitivity panel (IgG).
The treatment protocol integrates: dietary elimination (dairy, high-GI foods, gluten if anti-gliadin antibodies positive), gut restoration (L-glutamine 10 g/day, VSL#3 probiotics, SIBO treatment if confirmed), targeted nutrients (zinc 30–50 mg/day, omega-3 3–4 g/day, vitamin D to 60–80 ng/mL, niacinamide 500 mg/day, collagen peptides 10 g/day), hormonal optimization (DIM, berberine, saw palmetto as indicated), and topical support (niacinamide 4–10%, azelaic acid 15–20%, green tea EGCG 2% for rosacea).
If you are dealing with chronic skin conditions that haven’t responded to conventional treatment, a root-cause functional medicine approach targeting the gut-skin axis may be the missing piece. Our team at The Private Practice offers comprehensive evaluation and personalized skin protocols. Call (810) 206-1402 to schedule a consultation.
FAQ: Can healing the gut really clear skin conditions like acne and psoriasis?
Yes — the evidence is compelling. SIBO eradication clears rosacea in 96% of responders (Parodi 2008). Psoriasis patients show 10× higher intestinal permeability, and gut-targeted interventions including probiotics and dietary changes consistently improve psoriasis severity scores. Acne responds to gut microbiome restoration through multiple mechanisms: reduced LPS-driven sebaceous inflammation, improved estrogen metabolism via the estrobolome, and restoration of the butyrate-PPAR-γ axis that suppresses keratinocyte inflammation. While not every skin condition is purely gut-mediated, addressing gut dysbiosis is a high-yield first step in all four major inflammatory skin diseases.
FAQ: Is dairy really causing my acne?
For a significant subset of people, yes. Multiple epidemiological studies (Adebamowo 2005, 2006) and mechanistic evidence confirm that dairy — especially skim milk — activates mTORC1 via IGF-1 and leucine-rich whey protein, driving sebogenesis and comedone formation. The acne-dairy connection is strongest in individuals with insulin resistance or elevated IGF-1. A 4-week dairy elimination trial is a simple, free diagnostic test: if acne improves by ≥50%, dairy is a trigger. Fermented dairy (kefir, unsweetened yogurt with live cultures) is generally better tolerated due to altered growth factor bioavailability.
FAQ: What probiotics work best for eczema?
The evidence is strongest for prevention rather than treatment, and for early-life intervention. Lactobacillus rhamnosus HN001 and LGG (Lactobacillus rhamnosus GG) have the most robust data: multiple RCTs show 40–50% eczema risk reduction when administered during pregnancy and/or the first 6 months of life. For established eczema in children and adults, multi-strain probiotics including Lactobacillus salivarius LS01, Bifidobacterium breve Bbr8, and VSL#3 have shown SCORAD score improvements. The clinical response is most pronounced in patients with elevated IgE, food allergy-associated eczema, and those with documented gut dysbiosis on stool testing.
FAQ: What is the root cause of psoriasis and can it be reversed?
Psoriasis root causes include: gut microbiome dysbiosis driving Th17 overactivation; intestinal permeability allowing LPS translocation that sustains systemic inflammation; genetic Th17/IL-23 axis hyperresponsiveness (HLA-Cw06, IL-23R polymorphisms); and metabolic syndrome (insulin resistance, obesity increase psoriasis severity 2–3 fold). While complete reversal is not universal, significant and sustained improvement — even biologic-free remission — is achievable through a comprehensive protocol: gluten elimination (in anti-gliadin antibody-positive patients), gut restoration, omega-3 3–4 g/day, vitamin D optimization, anti-inflammatory diet, and stress reduction. In practice, many patients reduce biologic requirements or achieve stable PASI 50–75 improvement through functional interventions alone.